Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AXSM NASDAQ:NUVL NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$83.65+2.0%$48.59$4.77▼$83.87$6.12B0.581.04 million shs637,747 shsAXSMAxsome Therapeutics$122.00-1.2%$109.35$75.56▼$139.13$6.05B0.54507,815 shs576,593 shsNUVLNuvalent$79.54+3.4%$78.56$55.53▼$113.51$5.52B1.29406,504 shs720,647 shsWVEWAVE Life Sciences$8.00-16.8%$8.37$5.04▼$16.74$1.53B-1.151.54 million shs11.11 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.02%+5.31%+16.07%+926.38%+574.05%AXSMAxsome Therapeutics-1.19%+0.11%+14.51%+10.25%+36.08%NUVLNuvalent+3.43%+4.48%+1.52%+1.86%-4.90%WVEWAVE Life Sciences-16.84%-20.63%-8.57%+18.52%+44.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax3.2554 of 5 stars3.65.00.00.02.90.80.6AXSMAxsome Therapeutics4.7606 of 5 stars4.51.00.04.53.44.20.6NUVLNuvalent3.2305 of 5 stars4.50.00.00.03.63.30.0WVEWAVE Life Sciences4.6709 of 5 stars4.50.00.04.83.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.3310.38% UpsideAXSMAxsome Therapeutics 3.07Buy$177.8645.78% UpsideNUVLNuvalent 3.08Buy$119.3650.07% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.27153.33% UpsideCurrent Analyst Ratings BreakdownLatest WVE, ABVX, AXSM, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025WVEWAVE Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.009/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$163.009/2/2025NUVLNuvalentRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$105.008/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$112.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.008/4/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$150.008/4/2025WVEWAVE Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.007/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.007/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$24.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAXSMAxsome Therapeutics$385.69M15.78N/AN/A$1.46 per share83.56NUVLNuvalentN/AN/AN/AN/A$13.03 per shareN/AWVEWAVE Life Sciences$108.30M11.76N/AN/A$0.88 per share9.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAXSMAxsome Therapeutics-$287.22M-$5.07N/A43.26N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest WVE, ABVX, AXSM, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25AXSMAxsome Therapeutics1.661.571.51NUVLNuvalentN/A13.5713.57WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AXSMAxsome Therapeutics81.49%NUVLNuvalent97.26%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAXSMAxsome Therapeutics22.40%NUVLNuvalent10.20%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableWVE, ABVX, AXSM, and NUVL HeadlinesRecent News About These CompaniesJump Financial LLC Trims Stake in WAVE Life Sciences Ltd. $WVE2 hours ago | marketbeat.comWave RNA editing restores enzyme in genetic condition but underwhelms investors3 hours ago | fiercebiotech.comFWave shares sink on new study results for RNA editing drug3 hours ago | finance.yahoo.comForecasting The Future: 7 Analyst Projections For WAVE Life Sciences3 hours ago | benzinga.comWave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why3 hours ago | msn.comWave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference TranscriptSeptember 3 at 4:06 PM | seekingalpha.comWave Life Sciences stock tumbles after WVE-006 trial updateSeptember 3 at 8:11 AM | in.investing.comWave Life Sciences stock tumbles after WVE-006 trial updateSeptember 3 at 8:11 AM | in.investing.comWave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin DeficiencySeptember 3 at 7:30 AM | globenewswire.comDriehaus Capital Management LLC Sells 353,850 Shares of WAVE Life Sciences Ltd. $WVEAugust 31, 2025 | marketbeat.comSiren L.L.C. Cuts Stock Holdings in WAVE Life Sciences Ltd. $WVEAugust 31, 2025 | marketbeat.comWave Life Sciences Ltd. (WVE) Gains Momentum With Multiple RNA WinsAugust 29, 2025 | finance.yahoo.comWAVE Life Sciences Ltd. $WVE Shares Purchased by Charles Schwab Investment Management Inc.August 29, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Acquired by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Stock Position Raised by Martingale Asset Management L PAugust 28, 2025 | marketbeat.comGregory Verdine Sells 10,000 Shares of WAVE Life Sciences (NASDAQ:WVE) StockAugust 27, 2025 | insidertrades.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Sold by Maven Securities LTDAugust 23, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $1.02 Million Stock Position in WAVE Life Sciences Ltd. $WVEAugust 19, 2025 | marketbeat.com29,572 Shares in WAVE Life Sciences Ltd. (NASDAQ:WVE) Bought by Wealthedge Investment Advisors LLCAugust 18, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 7.8% - Still a Buy?August 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWVE, ABVX, AXSM, and NUVL Company DescriptionsAbivax NASDAQ:ABVX$83.65 +1.66 (+2.02%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$83.07 -0.58 (-0.69%) As of 05:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Axsome Therapeutics NASDAQ:AXSM$122.00 -1.47 (-1.19%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$121.66 -0.33 (-0.27%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Nuvalent NASDAQ:NUVL$79.54 +2.64 (+3.43%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$79.58 +0.03 (+0.04%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.WAVE Life Sciences NASDAQ:WVE$8.00 -1.62 (-16.84%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$7.78 -0.23 (-2.81%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
